tiprankstipranks
Blurbs

Analysts Conflicted on These Healthcare Names: Alphatec Holdings (ATEC), Arrowhead Pharmaceuticals (ARWR) and Insulet (PODD)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alphatec Holdings (ATECResearch Report), Arrowhead Pharmaceuticals (ARWRResearch Report) and Insulet (PODDResearch Report).

Alphatec Holdings (ATEC)

In a report released today, Amit Hazan from Goldman Sachs maintained a Hold rating on Alphatec Holdings, with a price target of $9.50. The company’s shares closed last Monday at $7.87.

According to TipRanks.com, Hazan is a 4-star analyst with an average return of 6.5% and a 55.0% success rate. Hazan covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Baxter International, and Intuitive Surgical.

Alphatec Holdings has an analyst consensus of Strong Buy, with a price target consensus of $13.92.

See today’s best-performing stocks on TipRanks >>

Arrowhead Pharmaceuticals (ARWR)

In a report released today, Madhu Kumar from Goldman Sachs maintained a Buy rating on Arrowhead Pharmaceuticals, with a price target of $65.00. The company’s shares closed last Monday at $45.63.

According to TipRanks.com, Kumar is a 5-star analyst with an average return of 18.1% and a 50.2% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Arvinas Holding Company, and Apellis Pharmaceuticals.

Arrowhead Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $71.63, implying a 54.0% upside from current levels. In a report issued on August 5, Chardan Capital also reiterated a Buy rating on the stock with a $82.00 price target.

Insulet (PODD)

Morgan Stanley analyst Cecilia Furlong maintained a Hold rating on Insulet today and set a price target of $273.00. The company’s shares closed last Monday at $264.85.

According to TipRanks.com, Furlong is a 5-star analyst with an average return of 20.6% and a 52.9% success rate. Furlong covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Bausch + Lomb Corporation, and Zimmer Biomet Holdings.

Currently, the analyst consensus on Insulet is a Moderate Buy with an average price target of $271.75, implying a 1.8% upside from current levels. In a report issued on August 5, Piper Sandler also maintained a Hold rating on the stock with a $235.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ATEC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More